## BSX: Boston Scientific Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.94 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-4.5% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($93.42)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. Boston Scientific Corporation (BSX): A Bull Case Theory**
- Source: Finviz | 20251205T180700 | Bullish | Relevance: 100%
- This article summarizes a bullish thesis on Boston Scientific Corporation (BSX), highlighting its potential for sustained 8-10% annual revenue growth, significant margin expansion, and double-digit EPS CAGR. Key drivers include structural growth in cardiology, electrophysiology, and minimally invasive technologies, with strong performance from products like Farapulse and Watchman. The company's innovation engine, healthy balance sheet, and strong free cash flow generation are expected to create substantial shareholder value.

**2. Boston Scientific gets European nod for Farapoint catheter**
- Source: MassDevice | 20251204T162135 | Bullish | Relevance: 100%
- Boston Scientific recently received CE mark for its Farapoint pulsed field ablation (PFA) catheter, allowing it to be marketed in Europe for treating right atrial flutter (AFL). This expands the indications for its Farapulse PFA platform, which was initially approved for AFib. The company aims to become a top player in the electrophysiology space, leveraging the Farapoint catheter's demonstrated efficacy and safety in preventing AFL recurrence.

**3. Quantbot Technologies LP Grows Holdings in Boston Scientific Corporation $BSX**
- Source: MarketBeat | 20251204T000801 | Bullish | Relevance: 100%
- Quantbot Technologies LP increased its stake in Boston Scientific Corporation (NYSE:BSX) by 17.5% in the second quarter, now owning 163,745 shares valued at $17.59 million, making it their 25th largest holding. Wall Street analysts maintain a "Buy" consensus rating for BSX with an average price target of $123.77, following strong Q3 earnings where the company beat estimates and provided positive FY2025 guidance. However, company insiders have sold approximately 125,782 shares worth $12.47 million in the past 90 days.

**4. Boston Scientific Stock (BSX) on December 3, 2025: Insider Sales, EU Device Win and Strong 2026 Price Targets**
- Source: ts2.tech | 20251203T233558 | Bullish | Relevance: 100%
- This article provides a detailed snapshot of Boston Scientific (BSX) stock on December 3, 2025, highlighting recent insider sales, a significant EU device approval for its Farapoint pulsed field ablation catheter, and strong analyst price targets for 2026. It also recaps the company's Q3 2025 earnings, growth drivers, valuation, and risks, indicating a premium-valued medtech leader with bullish prospects tempered by insider selling and high valuation.

**5. Boston Scientific executive exercises options, sells 17,313 shares | BSX SEC Filing - Form 4**
- Source: Stock Titan | 20251203T101050 | Neutral | Relevance: 100%
- An executive at Boston Scientific (BSX) exercised stock options for 17,313 shares at various prices and subsequently sold all 17,313 shares on the open market for a weighted average price of $101.5531 per share. These transactions, executed on December 1, 2025, were conducted under a pre-established Rule 10b5-1 trading plan. Following these sales, the executive directly holds 23,600 shares and indirectly holds 13,354 shares through a 401(k) plan.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | BTIG | $132 | $132 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | BTIG | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 3 ($1.31M) |
| Sells | 9 ($2.57M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 9.8% (-1.0%)
- Vanguard Group Inc: 9.3% (+0.8%)
- FMR, LLC: 6.7% (-8.2%)
- State Street Corpora: 4.4% (-0.4%)
- JPMORGAN CHASE & CO: 3.8% (+120.8%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-4.5% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.94 indicates undervaluation relative to growth. Balance sheet: $2.6B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $142.4B |
| Beta | 0.67 |
| 52W Range | $85.98 - $109.50 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.94 |
| Forward P/E | 28.1 |
| Current P/E | 32.1 |
| YoY Growth | 14.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -0.3% to -4.8% (-4.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.8pp (needs >4.0% for momentum thesis). Below SMA200 (0.96x), long-term trend not supportive. RSI neutral at 42. OFD pattern: -SBN (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.82% (CS: 12) | Weak |
| RSI_14 | 42.3 | Neutral |
| MACD Histogram | -0.28 | Bearish |
| vs SMA20 | 0.974x | Below |
| vs SMA50 | 0.983x | Below |
| vs SMA200 | 0.961x | Below |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $97.52
- **Stop Loss:** $93.42 (4.2% risk)
- **Target:** $105.72 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 121
- **Position Value:** $11,799.92
- **Portfolio %:** 11.80%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-04 (Est: $0.78)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.71 | $0.75 | +5.1% |
| 2025Q2 | $0.73 | $0.75 | +3.4% |
| 2025Q1 | $0.67 | $0.75 | +11.5% |
| 2024Q4 | $0.66 | $0.70 | +6.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*